Dr. Ruane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5901 W Olympic Blvd
Suite 401
Los Angeles, CA 90036Phone+1 323-954-1072Fax+1 323-954-1081- Is this information wrong?
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 1984 - 1987
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1981 - 1984
University College of Dublin National Univ SOMClass of 1978
Certifications & Licensure
CA State Medical License 1986 - 2025
MN State Medical License 1983 - 1986- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Clinical Trials
- Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment Start of enrollment: 2008 Mar 01
- Observational Registry Study of Quality of Life When Treating BTcP With Abstral Start of enrollment: 2013 Oct 01
- Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection Start of enrollment: 2014 Oct 01
Publications & Presentations
PubMed
- 22 citationsLenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-c...Samir K Gupta, Mezgebe Berhe, Gordon Crofoot, Paul Benson, Moti Ramgopal, James Sims, Cheryl McDonald, Peter Ruane, William E Sanchez, Anita Scribner, Shan-Yu Liu, Lau...> ;The Lancet. HIV. 2023 Jan 1
- 13 citationsImprovements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steat...Zobair M. Younossi, Maria Stepanova, Mazen Noureddin, Kris V. Kowdley, Simone I. Strasser, Anita Kohli, Peter Ruane, Mitchell L. Shiffman, Aasim Sheikh, Nadege Gunn, S...> ;Hepatology Communications. 2021 May 12
- 138 citationsCombination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHRohit Loomba, Mazen Noureddin, Kris V. Kowdley, Anita Kohli, Aasim Sheikh, Guy Neff, Bal R. Bhandari, Nadege Gunn, Stephen H. Caldwell, Zachary Goodman, Ilan Wapinski,...> ;Hepatology. 2021 Feb 1
- Join now to see all
Press Mentions
Descovy for PrEP Remains Safe and Effective at 96 WeeksNovember 21st, 2019
Gilead Demonstrates Non-Inferiority of Descovy to Truvada for HIV PrEPNovember 7th, 2019
Gilead Presents 96-Week Discover Trial Data Supporting Non-Inferior Efficacy and Key Safety Differences of Descovy for PrEP™ Compared with Truvada for PrEP®November 6th, 2019- Join now to see all
Hospital Affiliations
Cedars-Sinai Medical CenterLos Angeles, California- Olympia Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
